YOLFTbeta
Y-Biologics, Inc.

Y-Biologics, Inc.

338840 · KQ · Healthcare / Biotechnology

8,770.00KRW-130.00 (-1.46%)

Price History

Full chart

Market Stats

Previous Close8,900.00
Open8,890.00
Day Range8,720.00 – 9,270.00
52-Week Range7,230.00 – 38,000.00
Volume57.30K
Market Cap130.92B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.21
50-Day Avg8,993.20
200-Day Avg18,549.00

About

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Young Woo Park
  • Employees0
  • Headquarters#715-B, 17 Techno 4-ro, Daejeon, South Korea, Korea
  • Websitehttps://www.ybiologics.com

Leadership

  • Mr. Young Woo ParkCEO, President & Director · b. 1956
  • Woo-Ik JangCEO & Representative Director · b. 1956
  • Mr. Yeon Kyung LeeChief Financial Officer
  • Mr. Bum Chan ParkSenior VP, CTO & Director
  • Ms. Myeong Ja JangDirector of Legal/IP
  • Sang-heon LeeExecutive Director · b. 1967
  • Joo-han YoonExecutive Director · b. 1972

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.85B4.15B3.48B5.76B2.91B
Growth (%)--14.37%-16.18%+65.64%-49.45%
Cost of Revenue2.46B2.81B1.09B1.39B532.32M
Gross Profit2.39B1.34B2.39B4.37B2.38B
Gross Margin49.26%32.20%68.67%75.89%81.73%
Operating Expense19.75B20.08B23.77B11.49B11.65B
Operating Income-17.36B-18.75B-21.38B-7.12B-9.27B
Operating Margin-358.23%-451.70%-614.50%-123.46%-318.20%
EBITDA--15.74B-18.37B-4.36B-38.83B
EBITDA Margin--379.21%-528.10%-75.67%-1333.11%
Net Income-17.07B-18.80B-20.87B-6.44B-42.02B
Net Income Margin-352.17%-453.06%-599.90%-111.78%-1442.67%
R&D12.59B11.94B6.65B6.83B6.78B
R&D as % of Total Revenue259.70%287.71%191.14%118.49%232.85%
Interest Expense114.73M103.44M143.76M42.93M1.26B
Interest Expense % of Total Revenue2.37%2.49%4.13%0.75%43.23%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.24B29.32B30.29B21.73B55.80B
Total Liabilities9.80B17.03B6.89B3.37B29.20B
Total Equity28.44B12.29B23.41B18.36B26.60B
Cash16.87B12.61B20.54B9.08B38.92B

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.17B-10.10B-7.61B-4.14B-5.84B
Investing Cash Flow--759.15M3.71B-5.42B-
Financing Cash Flow-6.90B11.78B-1.93B-
Capital Expenditure7.57B1.10B196.14M2.86B1.42B
Free Cash Flow-16.74B-11.20B-7.80B-7.00B-7.26B
FCF to OCF182.58%110.86%102.58%169.04%124.40%

Earnings

Report DateDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------
EPS Actual-980.39-110.00-190.51-10.24-123.51-127.27-157.00-180.20-2313.47-284.45-510.00
Surprise-----------
Timing-----------

Key Statistics & Ratios

Market Cap130.92B
Enterprise Value106.10B
Trailing P/E0.00
Forward P/E0.00
Price / Sales41.30
Price / Book7.45
Revenue (TTM)3.17B
Gross Profit (TTM)2.56B
EBITDA-11.26B
Profit Margin0.00%
Operating Margin-244.87%
Return on Equity-297.87%
Return on Assets-23.92%
Shares Outstanding15.37M
Shares Float10.77M
Beta0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%